Research graph
References from Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR +/ HER2 ‐Negative Breast Cancer: A Real‐World Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Liquid Biopsy: From Discovery to Clinical Application
10.1158/2159-8290.cd-20-1311 · 2021 · External reference
Liquid Biopsy Into the Clinics: Current Evidence and Future Perspectives
10.1016/j.jlb.2024.100146 · 2024 · External reference
Circulating Tumor DNA to Monitor Treatment Response in Solid Tumors and Advance Precision Oncology
10.1038/s41698-025-00876-y · 2025 · External reference
Recent Advances in Liquid Biopsy for Precision Oncology: Emerging Biomarkers and Clinical Applications in Lung Cancer
10.1080/14796694.2025.2542051 · 2025 · External reference
Liquid Biopsy in Breast Cancer: Promises and Challenges
10.1097/cco.0000000000001168 · 2025 · External reference
Real‐World Clinical Practice and Outcomes in Peruvian Patients With Advanced EGFR T790M Mutation Positive NSCLC: A Multicenter Analysis
10.1016/j.ctarc.2025.100906 · 2025 · External reference
The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients With Advanced Melanoma
10.3390/cancers14030777 · 2022 · External reference
Real‐World Genome Profiling in Japanese Patients With Pancreatic Ductal Adenocarcinoma Focusing on HRD Implications
10.1111/cas.16329 · 2024 · External reference
Real‐World Data and Clinical Implications of Next‐Generation Sequencing (NGS)‐Based Analysis in Metastatic Breast Cancer Patients
10.3390/ijms25052490 · 2024 · External reference
Real‐World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated With Endocrine Agents After Exposure to Aromatase Inhibitors
10.3390/ijms241411419 · 2023 · External reference
Unresolved reference
2023 · External reference
EGFR Mutation Incidence in Non‐Small‐Cell Lung Cancer of Adenocarcinoma Histology: A Systematic Review and Global Map by Ethnicity (mutMapII)
2015 · External reference
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
10.1200/jco.2012.44.2806 · 2013 · External reference
Erlotinib Versus Standard Chemotherapy as First‐Line Treatment for European Patients With Advanced EGFR Mutation‐Positive Non‐Small‐Cell Lung Cancer (EURTAC): A Multicentre, Open‐Label, Randomised Phase 3 Trial
10.1016/s1470-2045(11)70393-x · 2012 · External reference
Overall Survival With Osimertinib in Untreated, EGFR‐ Mutated Advanced NSCLC
10.1056/nejmoa1913662 · 2020 · External reference
Afatinib Versus Gefitinib in Patients With EGFR Mutation‐Positive Advanced Non‐Small‐Cell Lung Cancer: Overall Survival Data From the Phase IIb LUX‐Lung 7 Trial
10.1093/annonc/mdw611 · 2017 · External reference
Updated Overall Survival Results From a Randomized Phase III Trial Comparing Gefitinib With Carboplatin‐Paclitaxel for Chemo‐Naive Non‐Small Cell Lung Cancer With Sensitive EGFR Gene Mutations (NEJ002)
10.1093/annonc/mds214 · 2013 · External reference
First‐Line Afatinib Versus Chemotherapy in Patients With Non‐Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
10.1016/j.jtho.2015.11.014 · 2016 · External reference
Osimertinib or Platinum‐Pemetrexed in EGFR T790M‐Positive Lung Cancer
10.1056/nejmoa1612674 · 2017 · External reference
Making the First Move in EGFR‐Driven or ALK‐Driven NSCLC: First‐Generation or Next‐ Generation TKI?
10.1038/s41571-018-0081-4 · 2018 · External reference
Treatment Approaches for EGFR‐Inhibitor‐ Resistant Patients With Non‐Small‐Cell Lung Cancer
10.1016/s1470-2045(15)00246-6 · 2015 · External reference
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
10.1126/scitranslmed.3002003 · 2011 · External reference
Acquired Resistance to TKIs in Solid Tumours: Learning From Lung Cancer
10.1038/nrclinonc.2014.104 · 2014 · External reference
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
10.1200/jco.2012.45.2029 · 2013 · External reference
Resistance Mechanisms to Osimertinib in EGFR‐Mutated Non‐Small Cell Lung Cancer
10.1038/s41416-019-0573-8 · 2019 · External reference
10.1080/1120009x.2026.2657116
10.1080/1120009x.2026.2657116 · External reference
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
10.1016/j.jtho.2021.06.017 · 2021 · External reference
ESMO Clinical Practice Guideline for the Diagnosis, Staging and Treatment of Patients With Metastatic Breast Cancer
10.1016/j.annonc.2021.09.019 · 2021 · External reference
Endocrine Treatment and Targeted Therapy for Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Metastatic Breast Cancer: ASCO Guideline Update
10.1200/jco.21.01392 · 2021 · External reference
Post‐CDK4/6 Inhibitor Treatment Landscape in Metastatic Hormone Receptor‐Positive Breast Cancer: A Narrative Review
10.1080/14737140.2025.2593540 · 2025 · External reference
ESR1 Mutation as an Emerging Clinical Biomarker in Metastatic Hormone Receptor‐Positive Breast Cancer
10.1186/s13058-021-01462-3 · 2021 · External reference
Elacestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy for Estrogen Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
10.1200/jco.22.00338 · 2022 · External reference
Design of SERENA‐6, a Phase III Switching Trial of Camizestrant in ESR1‐Mutant Breast Cancer During First‐Line Treatment
10.2217/fon-2022-1196 · 2023 · External reference
Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
10.1200/jco.23.00638 · 2023 · External reference
Switch to Fulvestrant and Palbociclib Versus no Switch in Advanced Breast Cancer With Rising ESR1 Mutation During Aromatase Inhibitor and Palbociclib Therapy (PADA‐1): A Randomised, Open‐Label, Multicentre, Phase 3 Trial
10.1016/s1470-2045(22)00555-1 · 2022 · External reference
First‐Line Camizestrant for Emerging ESR1‐Mutated Advanced Breast Cancer
10.1056/nejmoa2502929 · 2025 · External reference
New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
Sequential Liquid Biopsies Reveal Dynamic Alterations of EGFR Driver Mutations and Indicate EGFR Amplification as a New Mechanism of Resistance to Osimertinib in NSCLC
10.1016/j.lungcan.2017.04.004 · 2017 · External reference
Analysis of ESR1 Mutation in Circulating Tumor DNA Demonstrates Evolution During Therapy for Metastatic Breast Cancer
10.1126/scitranslmed.aac7551 · 2015 · External reference
Ultra‐Sensitive Mutation Detection and Genome‐Wide DNA Copy Number Reconstruction by Error Corrected Circulating Tumour DNA Sequencing
10.1373/clinchem.2018.289629 · 2018 · External reference
Durable Response to Nivolumab in a Patient With Hepatic Sarcomatoid Carcinoma: Evolutive Characterization of Genomic and Immunohistochemical PD‐L1 Expression Findings
10.1200/po.22.00163 · 2022 · External reference
Monitoring of T790M in Plasma ctDNA of Advanced EGFR‐Mutant NSCLC Patients on First‐ or Second‐Generation Tyrosine Kinase Inhibitors
10.1186/s12885-023-10698-5 · 2023 · External reference
Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor‐Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non‐Small Cell Lung Cancer During Treatment With Erlotinib
10.1002/cncr.28964 · 2014 · External reference
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation‐Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3
10.1016/j.jtho.2024.07.008 · 2024 · External reference
Landscape of EGFR‐Dependent and ‐Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR‐Mutant NSCLC
10.1158/1078-0432.ccr-18-1542 · 2018 · External reference
Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer
10.1056/nejmoa1713137 · 2018 · External reference
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib Plus Fulvestrant in the PALOMA‐3 Trial
10.1158/2159-8290.cd-18-0264 · 2018 · External reference
Tracking Evolution of Aromatase Inhibitor Resistance With Circulating Tumour DNA Analysis in Metastatic Breast Cancer
10.1093/annonc/mdx483 · 2018 · External reference
Prevalence of ESR1 Mutations in Cell‐Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO‐2 Clinical Trial
10.1001/jamaoncol.2016.1279 · 2016 · External reference
